Table 4.

Logistic regression of cataracts and demographic characteristics and ART duration among HIV+ participants

	N (%)	Crude prevalence OR, 95% CI	P-value	Adjusted prevalence OR, 95% CI*	P-value
Sex
Female	56/459 (12.2%)	REF	Ref	Ref	Ref
Male	45/203 (22.2%)	2.05 (1.33,3.16)	<0.01	1.66 (1.05, 2.59)	0.03
Age (continuous)		1.06 (1.04,1.09)	<0.01	1.05 (1.03,1.08)	<0.01
Age (categorical)
19-34	12/118 (10.2%)	Ref	Ref	Ref	Ref
35-49	44/369 (11.9%)	1.20 (0.63,2.45)	0.6	1.13 (0.59,2.31)	0.72
≥ 50	45/175 (25.7%)	3.06 (1.58,6.32)	<0.01	2.63 (1.34,5.49)	<0.01
ART duration (continuous)**		0.56 (0.33,0.94)	0.03	0.52 (0.30,0.88)	0.02
ART duration (categorical)
Non-ART	54/327(16.5%)	Ref	Ref	Ref	Ref
1-2 years	19/106 (17.9%)	1.10 (0.61, 1.94)	0.73	1.19 (0.64,2.13)	0.57
3-4 years	20/118 (16.9%)	1.03 (0.58, 1.79)	0.91	0.97 (0.53,1.71)	0.91
≥ 5 years	8/111 (7.2%)	0.39 (0.17, 0.81)	0.02	0.36 (0.15,0.75)	0.01

ART, antiretroviral therapy; HIV, human immunodeficiency virus; HLT, Holsmer-Lemeshow test; OR, odds ratio; CI, confidence interval

^*adjusted age and sex

^**report OR associated with every 5 years of more ART use